Adami first learned about CAR T in 2012 at a screening of Fire With Fire, the film about Emily Whitehead, the first pediatric ...

Even top academic centers struggle to keep pace with precision medicine, says William K. Oh, MD, who is prioritizing ...

The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.

Gay and bisexual men accounted for 79.8% of new HIV diagnoses in the US and dependent areas in 2024, according to the CDC.

Biomarker testing, referrals, screening, treatment access, and clinical trial barriers were examined during this recent IVBM. Precision therapies are transforming cancer outcomes, but operational and ...

In part 2, Christine Pfaff, RPh, MBA, explores reimbursement gaps, new payment models, and payer partnerships needed to expand cellular therapy access.

Employers need a voice at the table with health systems, hospitals, and carriers in shaping cancer care, according to Rosa ...

Young men aged 13 to 24 with HIV are more likely to be unaware of their HIV status than men in other age groups. Among gay and bisexual men more broadly, challenges such as racism, discrimination, and ...

Home phototherapy occupies an unusual position in the psoriasis treatment landscape: an option with randomized evidence of ...

Technology, particularly artificial intelligence (AI), represents the biggest structural shift in oncology drug development over the past 5 years, according to David Spigel, MD, p ...

Tavapadon (Juvmo) is the first selective D1/D5 dopamine receptor agonist approved for adult Parkinson disease, positioning a mechanistically differentiated oral, once-daily dopaminergic strategy.

Baricitinib is now FDA approved for adolescents 12 and older with severe alopecia areata, extending the once-daily pill ...